Riskpilot← Back to searchSign inGet full accessJereMed AB
ABActiveOrg 5593102022Norra Villavägen 2 BHospital activities · NACE 8610Est. 20210 employees
Revenue 2025
SEK 758K
+49% vs 2024
EBITDA margin
92.3%
+52% vs 2024
Equity ratio
95.8%
Financial strength
Net profit 2025
SEK 554K
+52% vs 2024
| Revenue | SEK 758K | +49% |
| EBITDA | SEK 700K | +52% |
| Net profit | SEK 554K | +52% |
| Total assets | SEK 963K | +65% |
| Equity | SEK 922K | +62% |
| Employees | 0 | — |
Legal name
JereMed AB
Org number
5593102022
Legal form
Aktiebolag
NACE code
8610 · Hospital activities
Founded
31 mars 2021
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva verksamhet inom medicinsk vård, särskilt barnmedicin, barnkardiologi, kirurgi och endoskopi samt därtill relaterade områden. Bolaget ska också bedriva konsultverksamhet och utbildning inom hälso- och sjukvård samt friskvård genom föreläsningar, kurser och seminarier inom ovan specificerade medicinska specialiteter.
Address
Norra Villavägen 2 B
Email
martinjeremiasen@hotmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 168 | 385 | 477 | 509 | 758 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 166 | 364 | 438 | 460 | 700 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 166 | 364 | 438 | 460 | 700 |
| Net financials | — | 0 | 0 | 2 | 2 |
| Profit before tax | 166 | 364 | 439 | 462 | 702 |
| Tax | −34 | −75 | −91 | −97 | −147 |
| Net profit | 132 | 289 | 347 | 365 | 554 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 191 | 388 | 444 | 583 | 963 |
| Equity | 157 | 336 | 423 | 568 | 922 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 34 | 53 | 21 | 14 | 41 |
| Total debt | 34 | 53 | 21 | 14 | 41 |
EBITDA margin
92.3%
This company
15.8%
Market median
+484% vs market
20212025
Equity ratio
95.8%
This company
38.2%
Market median
+151% vs market
20212025
Return on equity
60.1%
This company
18.4%
Market median
+227% vs market
20212025
Net profit margin
73.1%
This company
8.1%
Market median
+802% vs market
20212025
Asset turnover
0.79×
This company
1.12×
Market median
-29% vs market
20212025
Debt / equity
0.04×
This company
0.62×
Market median
+94% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-04-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JM Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2022 | |
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of JereMed AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Johan Martin Jeremiasen | Chief Executive Officer | 0 companies |
| Mats Einar Jeremiasen | Deputy Board Member | 0 companies |
| Ida Anna Elin Jeremiasen | Chairman | 0 companies |
| Rolf Carl Ragnar Ljung | Deputy Board Member | 0 companies |